NewsBenzingaArriVent、ESMOで消化器がんにおけるCDH17標的ADC ARR-217の第1相初期データを日曜に発表 後期治療ラインの大腸がん患者で6mg/kg投与時に44.8%の客観的奏効率を示す ArriVent、ESMOで消化器がんにおけるCDH17標的ADC ARR-217の第1相初期データを日曜に発表 後期治療ラインの大腸がん患者で6mg/kg投与時に44.8%の客観的奏効率を示す Benzinga 2026.10.25 17:59 (GMT+0) Open on Benzinga Other news Musk: SpaceX Has Completed $40 Billion GPU Debt Financing A $1 Trillion Depreciation Bomb Is Ticking Beneath the AI Market Verizon, Welltower On Deck Monday As Wireless Growth, Senior Housing Demand Face Test Wedbush Gives a Thumbs Up to Super Micro’s Preliminary Q1 Results. Troubles for SMCI Stock Could Finally Be in the Rear-View. Amkor Technology: Nvidia's $3 Billion Vote Of Confidence Lands On A De-Rated Stock (AMKR) Meta Q3: Non-Recurring Charge Hit GAAP Earnings, Q4 Capex Will Jump Sharply (NASDAQ:META)
Wedbush Gives a Thumbs Up to Super Micro’s Preliminary Q1 Results. Troubles for SMCI Stock Could Finally Be in the Rear-View.
